Active, Not Recruiting
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
NCT05273554
- Conditions
- Adenocarcinoma, Carcinoma, Neoplasms, +3 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States